Seleccione idioma:  
RTICC 2013
Programas RTICC
Seguimiento cientifico

Coordinador: Dr. Luis Montuenga Badia
Centro: Centro para la Investigación Médica Aplicada
Dirección postal: Avda. Pío XII, 55, 31008, Pamplona
Email: lmontuenga[arroba]unav.es

Breve CV: Dr. Luis M. Montuenga got his undergraduate degree with Honors in Biology from the University of Navarra (Spain). He also has a Master of Sciences (MSc) in Neuroendocrine Cell Biology from University College London (UK). In 1984 got his Ph.D. in Biology from the University of Navarra (Spain). He spent two years as postgraduate fellow at the Royal Postgraduate Medical School in London and was Visiting Scientist at the National Cancer Institute (NIH) in Bethesda (Maryland) during three years (1995-1998). He is currently Full Professor of Cell Biology at the School of Medicine of the University of Navarra and Senior Researcher and Head of the Oncology Division of the Center for Applied Medical Research (CIMA), University of Navarra. In the past Dr. Montuenga has been the Head of the Histology and Pathology Department of the School of Medicine (1998-2007) and Vicepresident of Research of the University of Navarra (2008-2011). 

Dr. Montuenga has authored more than 120 peer-reviewed publications in Cell Biology and Oncology, has directed 18 doctoral theses and has given numerous conferences and seminars internationally. His research activity is primarily focused on lung cancer. At the Center of Applied Medical Research he co-leads, together with Dr. Ruben Pio, the Laboratory of Lung Cancer Biomarkers. The laboratory of Biomarker’s is focused on the molecular mechanisms associated with the transformation of normal lung epithelial cells into lung tumors. One of its main translational aims is to find molecular markers related to lung carcinogenesis to develop new strategies for lung cancer early detection. Other research interest of the group is to design new molecular targeted therapies that may be useful in the treatment of lung tumors.

He has served as ad hoc reviewer in a variety of national and international research evaluation agencies and has been involved in the peer review process of a large number of journals of his research field.  He is currently Associate Editor of the Journal of Thoracic Oncology, the official journal of the International Association for the Study of Lung Cancer (IASLC).

He is founding member of the European Union Early Lung Cancer (EUELC), member of the prevention Committee of the IASLC, Active member of the American Association for Cancer Research (AACR) and the European Respiratory Society as well as Spanish scientific research societies like the Asociación Española de Investigación en Cáncer (ASEICA) or the Spanish Society for Cell Biology (SEBC).

In the past editions of the RTICC network, Dr. Montuenga has been the Coordinator for Training and Mobility and now serves as Coordinator of the Respiratory Tract Tumors Program.

Work Packages
Ensayos clínicos
Otros resultados
03/03/2017 | Otras reuniones
13/11/2016 | Otras reuniones
21/10/2016 | Reuniones RTICC
29/09/2016 | Becas
Lynch syndrome caused by germline PMS2 mutations: delineating the cancer risk.
ten Broeke SW, Brohet RM, Tops CM, van der Klift HM, Velthuizen ME, Bernstein I, Capellá Munar G, Gomez Garcia E, Hoogerbrugge N, Letteboer TG, Menko FH, Lindblom A, Mensenkamp AR, Moller P, van Os TA, Rahner N, Redeker BJ, Sijmons RH, Spruijt L, Suerink M, Vos YJ, Wagner A, Hes FJ, Vasen HF, Nielsen M, Wijnen JT
J Clin Oncol  2015.  4.  319-25.  PMID: 25512458. 

The effect of genotypes and parent of origin on cancer risk and age of cancer development in PMS2 mutation carriers.
Suerink M, van der Klift HM, Ten Broeke SW, Dekkers OM, Bernstein I, Capellá Munar G, Gomez Garcia E, Hoogerbrugge N, Letteboer TG, Menko FH, Lindblom A, Mensenkamp A, Moller P, van Os TA, Rahner N, Redeker BJ, Olderode-Berends MJ, Spruijt L, Vos YJ, Wagner A, Morreau H, Hes FJ, Vasen HF, Tops CM, Wijnen JT, Nielsen M
Genet Med  2016.  4.  405-9.  PMID: 26110232. 

Delineating the Phenotypic Spectrum of the NTHL1-Associated Polyposis.
Belhadj S, Mur P, Navarro M, González S, Moreno V, Capellá G, Valle L
Clin Gastroenterol Hepatol  2016.  PMID: 27720914. 
Grupos colaboradores: RD12/0036/0009 , RD12/0036/0031

Mutanome and expression of immune response genes in microsatellite stable colon cancer.
Sanz-Pamplona R, Gil-Hoyos R, López-Doriga A, Alonso MH, Aussó S, Molleví DG, Santos C, Sanjuán X, Salazar R, Alemany R, Moreno V
Oncotarget  2016.  14.  17711-25.  PMID: 26871478. 

A Vulnerability of a Subset of Colon Cancers with Potential Clinical Utility.
Vecchione L, Gambino V, Raaijmakers J, Schlicker A, Fumagalli A, Russo M, Villanueva A, Beerling E, Bartolini A, Mollevi DG, El-Murr N, Chiron M, Calvet L, Nicolazzi C, Combeau C, Henry C, Simon IM, Tian S, in 't Veld S, D'ario G, Mainardi S, Beijersbergen RL, Lieftink C, Linn S, Rumpf-Kienzl C, Delorenzi M, Wessels L, Salazar R, Di Nicolantonio F, Bardelli A, van Rheenen J, Medema RH, Tejpar S, Bernards R
Cell  2016.  2.  317-30.  PMID: 27058664. 

Gastrointestinal cancer: Light and shade of intrahepatic arterial radiotherapy in mCRC.
Tabernero J, Salazar R
Nat Rev Clin Oncol  2016.  8.  467-8.  PMID: 27296298. 
Grupos colaboradores: RD12/0036/0012 , RD12/0036/0031

Synthetic lethal interaction of cetuximab with MEK1/2 inhibition in NRAS-mutant metastatic colorectal cancer.
Queralt B, Cuyàs E, Bosch-Barrera J, Massaguer A, de Llorens R, Martin-Castillo B, Brunet J, Salazar R, Menendez JA
Oncotarget  2016.  PMID: 27636997. 

A novel germline POLE mutation causes an early onset cancer prone syndrome mimicking constitutional mismatch repair deficiency.
Wimmer K, Beilken A, Nustede R, Ripperger T, Lamottke B, Ure B, Steinmann D, Reineke-Plaass T, Lehmann U, Zschocke J, Valle L, Fauth C, Kratz CP
Fam Cancer  2016.  PMID: 27573199. 

Recent discoveries in the genetics of familial colorectal cancer and polyposis.
Valle L
Clin Gastroenterol Hepatol  2016.  PMID: 27712984. 

AMER1 Is a Frequently Mutated Gene in Colorectal Cancer--Letter.
Mur P, Aiza G, Sanz-Pamplona R, González S, Navarro M, Moreno V, Capellá G, Valle L
Clin Cancer Res  2015.  21.  4985.  PMID: 26527806. 

Ministerio de Economia y Competitividad
Red Temática Investigación Cooperativa Sanitaria
Rticc 2012
Red Temática Investigación Cooperativa en Cáncer (RTICC)
Centro de Investigación Cáncer - Campus Miguel de Unamuno - 37007 - Salamanca
(+34) 923294803 - sec.rticc[arroba]usal.es
Sobre la RTICC Programas RTICC Ofertas de empleo y Agenda Seguimiento científico
Red Temática de Investigación Cooperativa en Cáncer · © Copyright 2013 · sec.rticc[arrroba]usal.es · diseño web: detrazos